In 3 weeks, London will welcome over 80 leading international speakers to the 10th annual World Stem Cells & Regenerative Medicine Congress. Ahead of then we wanted to give you a taste of what you will hear on-site with some exclusive insights from these esteemed thought-leaders. We first published this e-Book back in February but now with even more speaker interviews, we wanted to share this updated and re-released version with you.
The past year has highlighted both the challenges to get market access in the cell therapy and regenerative medicine sectors but also how these therapies can overcome regulatory and financial hurdles to successfully treat the patients who need them the most.
We spoke to our revered speaker faculty to find out what they thought had been the biggest achievement in their respective industries over the last 12 months. Tim Bertram, Managing Director and CEO of RegenMedTX considers that “the biggest achievement in the past 12 months is reflected in the broadening acceptance by the investment, medical and patient communities that cell-based therapies have a place in the health-care armamentarium”.
Amongst the questions asked to the speakers, we wanted to find out who, either a person or company, they thought would be ‘the next big thing’. The responses were very much determined by which therapeutic field they were most interested in but Richard Grant, Global Vice President, Cell Therapy at Invetech, thinks that the ones to watch are “MesoBlast since they have been out front with the aggressive trial schedule that they have undertaken”.
Finally we concluded the speaker interviews but asking them all what they think will be the biggest topic of discussion at this year’s event. Paul Wotton, President & CEO at Ocata Therapeutics, foresees the biggest talking point at the conference to be “how to commercialise stem cell based therapies successfully. The industry is beginning to achieve a degree of maturity where commercialization is a reality”.